Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Inclusion Criteria: * Written informed consent before any study related procedure * Male and female patients age 18 years or older at time of enrollment * Diagnosis of intestinal obstruction of malignant origin * In case of peritoneal carcinomatosis, confirmation by CT or MRI scan within the 3 months preceding the inclusion in the study * Confirmed as inoperable after surgical advice * Patient with a nasogastric tube OR presenting with 3 or more episodes of vomiting / 24h in the last 48 hours * Estimated life expectancy 1 month or more Exclusion Criteria: * Operable obstruction or subobstruction * Bowel obstruction due to a non-malignant cause * Signs of bowel perforation * Prior treatment with somatostatin or any other analogue within the previous 60 days * A known hypersensitivity to any of the study treatments or related compounds * Previous participation in this study * Is likely to require treatment during the study with drugs that are not permitted by the study protocol * Has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the subject's safety